



For Immediate Release
January 7, 2009

Media Contact:
Erin Emlock
(617) 768-6923

Genzyme Diagnostics Launches New Kidney Disease Test

----- Cystatin C Assay Utilizes Unique Methodology

FRAMINGHAM, Mass. – Genzyme Diagnostics, a business unit of Genzyme Corp., today announced the launch of its Cystatin C assay, a new test to aid in the diagnosis and monitoring of kidney disease.

“This test is an important addition to our line of renal clinical chemistry products, and an example of our ongoing effort to build an even broader portfolio in this area,” stated Genzyme Diagnostics President Donald Pogorzelski. “Our goal is to improve the care of kidney disease patients, and our Cystatin C assay expands the range of tools we offer physicians to enhance their ability to assess kidney function.”

Cystatin C is an early marker used in the determination of mild renal impairment, and is particularly useful, when compared to a single serum creatinine test, due to its constant production, and independence of outside factors such as of muscle mass, age or sex. Genzyme Diagnostics markets a number of clinical chemistry tests to assess kidney function, including creatinine, microalbumin, urea, and others.

How the test works

The Genzyme Cystatin C assay uses a colloidal gold methodology that is unique to the cystatin C marketplace and is intended for the measurement of cystatin C

concentration in human serum, heparinized plasma, or EDTA plasma. It is optimized for use on multiple automated clinical chemistry analyzers and is 510k approved and CE marked.

About Genzyme Diagnostics

Genzyme Diagnostics offers a unique product portfolio for diagnostic manufacturers and clinical laboratories worldwide, supplying raw materials, formulated reagents and point-of-care rapid diagnostic tests. Its products focus on cardiovascular disease, diabetes, renal function testing, and infectious disease. Genzyme Diagnostics is a business unit of Genzyme Corporation. For more information please visit www.genzymediagnosics.com

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of \$3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as

cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.

Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

#